Initiation of tocilizumab or baricitinib were associated with comparable clinical outcomes among patients hospitalized with covid-19 and treated with dexamethasone

HIGHLIGHTS

• who: Carlos K. H. Wong and collaborators from the Ageing, India University of Studies Gd`Annunzio have published the article: Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone, in the Journal: (JOURNAL)
• what: Based on a territory-wide cohort of patients hospitalized with COVID-19, the study has offered the much-needed evidence on a head-to-head comparison between tocilizumab and baricitinib, establishing their safety and efficacy on top of background dexamethasone use. Among hospitalized patients with moderate-to-severe COVID . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.